387 related articles for article (PubMed ID: 1280735)
1. Acute inhibition of endopeptidase 24.11 in essential hypertension: SCH 34826 enhances atrial natriuretic peptide and natriuresis without lowering blood pressure.
Richards AM; Crozier IG; Espiner EA; Ikram H; Yandle TG; Kosoglou T; Rallings M; Frampton C
J Cardiovasc Pharmacol; 1992; 20(5):735-41. PubMed ID: 1280735
[TBL] [Abstract][Full Text] [Related]
2. Enhanced sodium retention after acute nitric oxide blockade in mildly sodium loaded patients with essential hypertension.
Bech JN; Nielsen EH; Pedersen RS; Svendsen KB; Pedersen EB
Am J Hypertens; 2007 Mar; 20(3):287-95. PubMed ID: 17324742
[TBL] [Abstract][Full Text] [Related]
3. Hemodynamic and humoral effects of chronic treatment with the neutral endopeptidase inhibitor SCH 42495 in spontaneously hypertensive rats.
Sala C; Monopoli A; Casati C; Ardeleani G; Ongini E; Zanchetti A; Morganti A
J Cardiovasc Pharmacol; 1994 May; 23(5):703-8. PubMed ID: 7521451
[TBL] [Abstract][Full Text] [Related]
4. [The effects of the acute administration of atrial natriuretic peptide on the mechanisms regulating diuresis and natriuresis in the essential hypertension patient].
Iannettone CM; Strazzulla G; Fabbri G; Piazza E; Valenza T; De Feo ML; Franchi F
Ann Ital Med Int; 1991; 6(3):273-83. PubMed ID: 1837999
[TBL] [Abstract][Full Text] [Related]
5. Prolonged inhibition of endopeptidase 24.11 in normal man: renal, endocrine and haemodynamic effects.
Richards AM; Wittert G; Espiner EA; Yandle TG; Frampton C; Ikram H
J Hypertens; 1991 Oct; 9(10):955-62. PubMed ID: 1658138
[TBL] [Abstract][Full Text] [Related]
6. Effects of felodipine on natriuresis, atrial natriuretic factor, the renin-angiotensin-aldosterone system, and blood pressure in essential hypertension.
Cerasola G; Cottone S; Mangano MT; D'Ignoto G; Pinto A; Carone MB
Clin Ther; 1988; 10(6):694-703. PubMed ID: 2975530
[TBL] [Abstract][Full Text] [Related]
7. Renal tubular sensitivity to atrial natriuretic factor in essential hypertension.
Janssen WM; de Zeeuw D; van der Hem GK; de Jong PE
J Hypertens; 1994 Apr; 12(4):439-47. PubMed ID: 8064168
[TBL] [Abstract][Full Text] [Related]
8. Pressure-dependent distal tubular action of atrial natriuretic peptide in healthy humans.
Eiskjaer H; Nielsen CB; Pedersen EB
J Hypertens; 1996 Jan; 14(1):99-106. PubMed ID: 12013501
[TBL] [Abstract][Full Text] [Related]
9. Endopeptidase 24.11 inhibition by SCH 42495 in essential hypertension.
Richards AM; Crozier IG; Kosoglou T; Rallings M; Espiner EA; Nicholls MG; Yandle TG; Ikram H; Frampton C
Hypertension; 1993 Jul; 22(1):119-26. PubMed ID: 8391513
[TBL] [Abstract][Full Text] [Related]
10. Effects of statins on renal sodium and water handling: acute and short-term effects of atorvastatin on renal haemodynamics, tubular function, vasoactive hormones, blood pressure and pulse rate in healthy, normocholesterolemic humans.
Paulsen L; Holm C; Bech JN; Starklint J; Pedersen EB
Nephrol Dial Transplant; 2008 May; 23(5):1556-61. PubMed ID: 18065809
[TBL] [Abstract][Full Text] [Related]
11. Regulation of glomerular filtration in essential hypertension: role of abnormal Na+ transport and atrial natriuretic peptide.
Semplicini A; Ceolotto G; Sartori M; Maresca A; Baritono E; De Toni R; Paparella I; Calò L
J Nephrol; 2002; 15(5):489-96. PubMed ID: 12455714
[TBL] [Abstract][Full Text] [Related]
12. [Effect of sinorphan, an endopeptidase inhibitor on severe congestive cardiac insufficiency].
Varin J; Duboc D; Weber S; Fouchard J; Schwartz JC; Muffat-Joly M; Guérin F
Arch Mal Coeur Vaiss; 1991 Oct; 84(10):1465-71. PubMed ID: 1662033
[TBL] [Abstract][Full Text] [Related]
13. Effects of atrial natriuretic factor on natriuresis and cGMP in patients with essential hypertension.
Cusson JR; Hamet P; Gutkowska J; Kuchel O; Genest J; Cantin M; Larochelle P
J Hypertens; 1987 Aug; 5(4):435-43. PubMed ID: 2822796
[TBL] [Abstract][Full Text] [Related]
14. Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension.
Favrat B; Burnier M; Nussberger J; Lecomte JM; Brouard R; Waeber B; Brunner HR
J Hypertens; 1995 Jul; 13(7):797-804. PubMed ID: 7594444
[TBL] [Abstract][Full Text] [Related]
15. Atrial natriuretic factor: pharmacokinetics and cyclic GMP response in relation to biologic effects in severe heart failure.
Moe GW; Canepa-Anson R; Armstrong PW
J Cardiovasc Pharmacol; 1992 May; 19(5):691-700. PubMed ID: 1381766
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of dual ACE/NEP inhibitor GW660511X in mild-to-moderate hypertensive patients.
Johnson AG; Pearce GL; Danoff TM
J Hum Hypertens; 2006 Jul; 20(7):496-503. PubMed ID: 16543907
[TBL] [Abstract][Full Text] [Related]
17. Normal renal tubular response to changes of sodium intake in hypertensive man.
Bruun NE; Skøtt P; Damkjaer Nielsen M; Rasmussen S; Schütten HJ; Leth A; Pedersen EB; Giese J
J Hypertens; 1990 Mar; 8(3):219-27. PubMed ID: 2159502
[TBL] [Abstract][Full Text] [Related]
18. Renal response to candoxatrilat in patients with heart failure.
Good JM; Peters M; Wilkins M; Jackson N; Oakley CM; Cleland JG
J Am Coll Cardiol; 1995 May; 25(6):1273-81. PubMed ID: 7722120
[TBL] [Abstract][Full Text] [Related]
19. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension.
Bevan EG; Connell JM; Doyle J; Carmichael HA; Davies DL; Lorimer AR; McInnes GT
J Hypertens; 1992 Jul; 10(7):607-13. PubMed ID: 1321186
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular and renal effects of low-dose atrial natriuretic peptide in compensated cirrhosis.
La Villa G; Lazzeri C; Pascale A; Sestini S; Bisi G; Sciagrà R; Vecchiarino S; Raggi VC; Barletta G; Laffi G; Gentilini P
Am J Gastroenterol; 1997 May; 92(5):852-7. PubMed ID: 9149200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
